Business
Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021
The Company's Dual-Receptor Agonists Demonstrate Potent Weight Loss and Improve Metabolic Profile in Diet-Induced Obese Mice Company Plans to Initiate
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"The Company's Dual-Receptor Agonists Demonstrate Potent Weight Loss and Improve Metabolic Profile in Diet-Induced Obese Mice\n Company Plans to Initiate First-in-Human Clinical Trial in Coming Months\n\n\nSAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of preclinical data from a series of internally developed dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors at ObesityWeek® 2021. The presentations highlight the effects of treatment on body weight and metabolic profile in diet-induced obese (DIO) mice as compared to control cohorts treated with vehicle, the GLP-1 agonist semaglutide, or the dual GLP-1/GIP agonist tirzepatide. The studies are summarized in two poster presentations at the annual meeting of The Obesity Society, being held virtually November 1-5, 2021. \n\n \n \n \n \n \n \n\n \nThe results of the studies demonstrate that addition of GIP receptor activity improves upon the observed effects resulting from activation of the GLP-1 receptor alone in DIO mouse models. Weight loss, glucose, and insulin effects are enhanced in the Viking series of dual-agonist compounds compared to the effects observed with the GLP-1 agonist comparator, semaglutide, when administered at the same dose for the same time period.\nIn separate studies, the effect sizes observed with the Viking series of dual agonists were similar to those observed following treatment with tirzepatide, a dual GLP-1/GIP receptor agonist currently in clinical development. Reductions in liver fat content were generally numerically larger among animals treated with Viking compounds relative to liver fat reductions observed among tirzepatide-treated animals.\nHighlights from the poster presentations are summarized below.\nPoster 206: Novel Co-Agonists of GLP-1 and GIP Receptors Produce Robust Weight Loss in a Rodent Model of Obesity\n21-day study comparing a series of novel GLP-1/GIP dual agonists to vehicle and to the GLP-1 agonist semaglutide Treatment with Viking dual agonists resulted in mean reductions in body weight of up to 27% relative to vehicle (p","length":3021,"tagName":"div"}]